Alzheimer's disease
Conditions
Interventions
The YZQXD group:Yizhiqingxin decoction(YZQXD) granules (1 bag, twice daily),take 3 months continuously.
The control group:donepezil hydrochloride tablets(5mg/tablet),1 tablet orally at bedtime daily,increasing to 2 tablets at bedtime after 4 weeks of dose maintenance for 3 months.
Sponsors
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Eligibility
Sex/Gender
All
Age
50 Years to 85 Years
Inclusion criteria
Inclusion criteria: (1) Age = 50 years, = 85 years, male or female. (2) Meet the diagnostic criteria of the National Institute of Neurological Disorders, Speech Disorders, and Stroke Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA). (3) Meet the diagnostic criteria for dementia with evidence of deficiency, blood-stasis and toxic. (4) Patients with mild to moderate disease: total score of 10-26 on the Simple Mental State Examination; score of 1-2 on the Clinical Dementia Rating Scale; total score of =4 on the Harkinski Ischemia Index. (5) Patients for whom there had been head scans (CT or MRI) imaging evidence supporting the diagnosis of AD, and these head scans were performed in the past one year or before enrollment. (6) Sufficient visual and auditory discrimination to undergo neuropsychological testing. (7) A certain level of literacy, with the ability to read simple texts and write simple sentences in the past. (8) have a stable caregiver; voluntary and legal guardian consent to participate, and jointly sign an informed.
Exclusion criteria
Exclusion criteria: (1) Other causes of dementia such as vascular dementia, Lewy body dementia or frontotemporal dementia, etc. Dementia symptoms caused by other diseases such as vitamin B12 or folate deficiency, hypothyroidism, etc. (2) Other neurological or psychiatric diseases that cause dementia such as Parkinson's disease, Huntington's disease, hydrocephalus, severe traumatic brain injury, alcoholic encephalopathy, depression, schizophrenia, or epilepsy, etc. (3) Patients with liver or kidney abnormalities. (4) Those who have taken other Chinese medicines containing the herbal ingredients of this test within 1 month. (5) Those who have taken cholinergic drugs, anticholinergic drugs or drugs that affect cognitive function during the same period. (6) Allergic persons or those who are allergic to the ingredients of the study drugs.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| score of the Alzheimer’s Disease Assessment Scale–Cognitive Subscale (ADAS-Cog); | — |
Secondary
| Measure | Time frame |
|---|---|
| score of the Mini-mental State Examination(MMSE);score of the Activity of Daily Living Scale(ADL);score of the Chinese Medicine syndrome Score Scale(deficiency,blood-stasis and toxic syndrome); | — |
Countries
China
Contacts
Public ContactPei Hui
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Outcome results
None listed